203 related articles for article (PubMed ID: 22675707)
1. Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography.
Moschouris H; Malagari K; Gkoutzios P; Kalokairinou M; Stamatiou K; Chatzimichail K; Kornezos I; Karagiannis E; Kiltenis M; Papadaki MG
Med Ultrason; 2012 Jun; 14(2):87-94. PubMed ID: 22675707
[TBL] [Abstract][Full Text] [Related]
2. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
[TBL] [Abstract][Full Text] [Related]
3. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
Takada J; Hidaka H; Nakazawa T; Kondo M; Numata K; Tanaka K; Matsunaga K; Okuse C; Kobayashi S; Morimoto M; Ohkawa S; Koizumi W
BMC Res Notes; 2015 Oct; 8():609. PubMed ID: 26502722
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.
Sugimoto K; Moriyasu F; Saito K; Rognin N; Kamiyama N; Furuichi Y; Imai Y
Liver Int; 2013 Apr; 33(4):605-15. PubMed ID: 23305331
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
Kawaoka T; Aikata H; Murakami E; Nakahara T; Naeshiro N; Tanaka M; Honda Y; Miyaki D; Nagaoki Y; Takaki S; Hiramatsu A; Waki K; Takahashi S; Chayama K
Oncology; 2012; 83(4):192-200. PubMed ID: 22890083
[TBL] [Abstract][Full Text] [Related]
6. Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.
Zocco MA; Garcovich M; Lupascu A; Di Stasio E; Roccarina D; Annicchiarico BE; Riccardi L; Ainora ME; Ponziani F; Caracciolo G; Rapaccini GL; Landolfi R; Siciliano M; Pompili M; Gasbarrini A
J Hepatol; 2013 Nov; 59(5):1014-21. PubMed ID: 23811306
[TBL] [Abstract][Full Text] [Related]
7. Contrast-enhanced ultrasonography for evaluating antiangiogenic treatment in hepatocellular carcinoma. A long way from research to clinical practice.
Spârchez Z
Med Ultrason; 2012 Jun; 14(2):85-6. PubMed ID: 22675706
[No Abstract] [Full Text] [Related]
8. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
Meyer T; Palmer DH; Cheng AL; Hocke J; Loembé AB; Yen CJ
Liver Int; 2017 Jul; 37(7):1047-1055. PubMed ID: 28066978
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study.
Shiozawa K; Watanabe M; Kikuchi Y; Kudo T; Maruyama K; Sumino Y
World J Gastroenterol; 2012 Oct; 18(40):5753-8. PubMed ID: 23155317
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
Sacco R; Bargellini I; Ginanni B; Bertini M; Faggioni L; Federici G; Romano A; Bertoni M; Metrangolo S; Altomare E; Parisi G; Tumino E; Scaramuzzino A; Bresci G; Bartolozzi C
Expert Rev Anticancer Ther; 2012 Jul; 12(7):869-75. PubMed ID: 22845401
[TBL] [Abstract][Full Text] [Related]
11. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
[TBL] [Abstract][Full Text] [Related]
12. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
Dig Dis; 2014; 32(6):705-10. PubMed ID: 25376287
[TBL] [Abstract][Full Text] [Related]
13. Early response to anti-tumoral treatment in hepatocellular carcinoma--can quantitative contrast-enhanced ultrasound predict outcome?
Knieling F; Waldner MJ; Goertz RS; Zopf S; Wildner D; Neurath MF; Bernatik T; Strobel D
Ultraschall Med; 2013 Feb; 34(1):38-46. PubMed ID: 23258770
[TBL] [Abstract][Full Text] [Related]
14. Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results.
Frampas E; Lassau N; Zappa M; Vullierme MP; Koscielny S; Vilgrain V
Eur J Radiol; 2013 May; 82(5):e205-11. PubMed ID: 23273822
[TBL] [Abstract][Full Text] [Related]
15. Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma.
Kim MJ; Choi JI; Lee JS; Park JW
J Gastroenterol Hepatol; 2011 Jul; 26(7):1201-6. PubMed ID: 21371120
[TBL] [Abstract][Full Text] [Related]
16. Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area.
Granata V; de Lutio di Castelguidone E; Fusco R; Catalano O; Piccirillo M; Palaia R; Izzo F; Gallipoli AD; Petrillo A
Radiol Med; 2016 Feb; 121(2):122-31. PubMed ID: 26345332
[TBL] [Abstract][Full Text] [Related]
17. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil.
Hsu CY; Shen YC; Yu CW; Hsu C; Hu FC; Hsu CH; Chen BB; Wei SY; Cheng AL; Shih TT
J Hepatol; 2011 Oct; 55(4):858-65. PubMed ID: 21338641
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results.
Salvaggio G; Furlan A; Agnello F; Cabibbo G; Marin D; Giannitrapani L; Genco C; Midiri M; Lagalla R; Brancatelli G
Radiol Med; 2014 Apr; 119(4):215-21. PubMed ID: 24297581
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.
Lee JH; Park JY; Kim DY; Ahn SH; Han KH; Seo HJ; Lee JD; Choi HJ
Liver Int; 2011 Sep; 31(8):1144-9. PubMed ID: 21745288
[TBL] [Abstract][Full Text] [Related]
20. Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib.
Dai X; Schlemmer HP; Schmidt B; Höh K; Xu K; Ganten TM; Ganten MK
Eur J Radiol; 2013 Feb; 82(2):327-34. PubMed ID: 23246016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]